Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone palmitate in acute schizophrenia
NCT01527305Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2012
- Primary completion
- Dec 2013
- Modality
- Metabolically Activated Prodrugs
- Countries
- 4
01
Overview
Phase 4, open-label, single-arm trial of paliperidone palmitate in schizophrenia, sponsored by Janssen Pharmaceutical. Primary endpoint: Change From Baseline in Positive and Negative Syndrome Scale Total Score at 13 weeks. Started Jun 2012; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01527305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01527305.